Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?
- 14 July 2010
- journal article
- review article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 51 (10), 1805-1815
- https://doi.org/10.3109/10428194.2010.496506
Abstract
Ribavirin was discovered nearly 40 years ago as a broad-spectrum antiviral drug. Recent data suggest that ribavirin may also be an effective cancer therapy. In this case, ribavirin targets an oncogene, the eukaryotic translation initiation factor eIF4E, elevated in approximately 30% of cancers including many leukemias and lymphomas. Specifically, ribavirin impedes eIF4E mediated oncogenic transformation by acting as an inhibitor of eIF4E. In a phase II clinical trial, ribavirin treatment led to substantial clinical benefit in patients with poor-prognosis acute myeloid leukemia (AML). Here molecular targeting of eIF4E correlated with clinical response. Ribavirin also targets a key enzyme in the guanosine biosynthetic pathway, inosine monophosphate dehydrogenase (IMPDH), and also modulates immunity. Parallels with known antiviral mechanisms could be informative; however, after 40 years, these are not entirely clear. The antiviral effects of ribavirin appear cell-type specific. This variation likely arises for many reasons, including cell specific variations in ribavirin metabolism as well as virus specific factors. Thus, it seems that the mechanisms for ribavirin action in cancer therapy may also vary in terms of the cancer/tissue under study. Here we review the anticancer activities of ribavirin and discuss the possible utility of incorporating ribavirin into diverse cancer therapeutic regimens.Keywords
This publication has 101 references indexed in Scilit:
- Structural characterization of the Z RING-eIF4E complex reveals a distinct mode of control for eIF4EProceedings of the National Academy of Sciences of the United States of America, 2010
- Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck CancerJournal of Oncology, 2009
- Eukaryotic Initiation Factors (eIF) 2α and 4E Expression, Localization, and Phosphorylation in Brain TumorsJournal of Histochemistry & Cytochemistry, 2009
- Pondering the puzzle of PML (promyelocytic leukemia) nuclear bodies: Can we fit the pieces together using an RNA regulon?Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2008
- Ribavirin targets eIF4E dependent Akt survival signalingBiochemical and Biophysical Research Communications, 2008
- The eIF4E RNA regulon promotes the Akt signaling pathwayThe Journal of cell biology, 2008
- Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicityJCI Insight, 2007
- Viral Determinants of Resistance to Treatment in Patients with Hepatitis CClinical Microbiology Reviews, 2007
- eIF4E is a central node of an RNA regulon that governs cellular proliferationThe Journal of cell biology, 2006
- High eIF4E, VEGF, and Microvessel Density in Stage I to III Breast CancerAnnals of Surgery, 2006